Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in Patients With BRAF V600-Mutant Metastatic Colorectal Cancer

NCT07790510 is registered in ClinicalTrials.gov with Haisco Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT07790510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07790510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in Patients With BRAF V600-Mutant Metastatic Colorectal Cancer
Lead sponsor
Haisco Pharmaceutical Group Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 12, 2026
Completion date
September 30, 2030
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer (crc)